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Economic evaluation of human papillomavirus vaccination
in the United Kingdom
Mark Jit, health economist and mathematical modeller, Yoon Hong Choi, mathematical modeller,
W John Edmunds, head of modelling and economics unit
ABSTRACT
Objective To assess the cost effectiveness of routine
vaccination of 12 year old schoolgirls against human
papillomavirus infection in the United Kingdom.
Design Economic evaluation.
Setting UK.
Population Schoolgirls aged 12 or older.
Main outcomemeasuresCosts, quality adjusted life years
(QALYs), and incremental cost effectiveness ratios for a
range of vaccination options.
Results Vaccinating 12 year old schoolgirls with a
quadrivalent vaccine at 80% coverage is likely to be cost
effective at a willingness to pay threshold of £30000
(€37700; $59163) per QALY gained, if the average
duration of protection from the vaccine is more than
10 years. Implementing a catch-up campaign of girls up to
age 18 is likely to be cost effective. Vaccination of boys is
unlikely to be cost effective. A bivalent vaccine with the
sameefficacyagainst humanpapillomavirus types16and
18 costing £13-£21 less per dose (depending on the
duration of vaccine protection)may be as cost effective as
the quadrivalent vaccine although less effective as it does
not prevent anogenital warts.
ConclusionsRoutinevaccinationof12yearoldschoolgirls
combined with an initial catch-up campaign up to age 18
is likely tobecosteffective in theUK. The resultsare robust
to uncertainty in many parameters and processes. A key
influential variable is the duration of vaccine protection.
INTRODUCTION
Human papillomaviruses are responsible for nearly
3000 cases of cervical cancer1 and more than 100 000
diagnosed cases of anogenital warts2 in the United
Kingdom every year, despite a decrease in the
incidence of cervical cancer as a result of regular
cytological screening. In particular, human papilloma-
virus types 16 and 18 are associated with 70% of
cervical cancers,3 whereas 90% of anogenital warts are
linked to human papillomavirus types 6 and 11.4 In
addition, human papillomavirus has been linked to
anal, vulval, vaginal, penile, and oropharyngeal
cancers.5 Two prophylactic vaccines against human
papillomavirus (a bivalent vaccine against types 16 and
18 and a quadrivalent vaccine that also includes types 6
and 11) have been shown to be efficacious in up to five
years of follow-up against types 16 and 18 cervical
infection and associated disease as well as against
anogenital warts.6 7 In addition, the results from clinical
trials suggest that both vaccines may offer partial
protection against oncogenic human papillomavirus
types not in the vaccine.7 8 Both vaccines have the
potential to bring a decrease in the incidence of human
papillomavirus related disease and are being consid-
ered for routine immunisation in many countries.
Information about the epidemiological and economic
impact of adding vaccination to the cervical screening
system is required for a decision to be made about
whether and how to introduce vaccination.
In the UK the Department of Health has announced
a routine human papillomavirus immunisation pro-
gramme for schoolgirls aged 12 or 13, starting from
September 2008, with a two year catch-up programme
for girls up to 18.9 The announcement follows advice
from the Joint Committee on Vaccination and
Immunisation, which considered the cost effectiveness
of different options such as vaccinating at different
ages, extending vaccination to boys, and incorporating
a catch-up campaign for girls older than the age for
routine vaccination. The samecost effectivenessmodel
was later used to inform the adjudication process
between the twovaccines,which led to adecision touse
the bivalent vaccine in the UK immunisation pro-
gramme.
We describe the cost effectiveness model used to
inform decisions about human papillomavirus vacci-
nation in the UK. Our model considers the impact of
vaccination on squamous cell carcinomas, adenocarci-
nomas, cervical cancers due to high risk human
papillomavirus types not in the vaccine, non-cervical
cancers, and anogenital warts.
METHODS
Model
We used a transmission dynamic model to predict the
burdenofhumanpapillomavirus relateddisease for the
number of cervical screens, treatments for precancer-
ous abnormalities of the cervix, and cases of diagnosed
cancer and anogenital warts expected before and after
vaccination.10 The model incorporated sexual trans-
mission to take into account the additional benefit of
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herd immunity. The population was stratified by
papillomavirus type, age, sex, and sexual activity
based risk group. Papillomavirus types were split into
three groups for cervical cancers (type 16, type 18, and
other high risk types) and two groups for anogenital
warts (type 6 and type 11).
For high risk papillomavirus types causing squa-
mous cell carcinomas, we used type specific model
compartments to represent being susceptible to infec-
tion, infected with human papillomavirus or immune
to infection. Infected states in females were subdivided
into being free of disease, having cervical intra-
epithelial neoplasias of different grades (1, 2, or 3),
havingcarcinoma in situorundiagnosedsquamouscell
carcinoma and having diagnosed invasive squamous
cell carcinoma. We adopted the same structure for
adenocarcinomas, with states for cervical glandular
intraepithelial neoplasia replacing cervical intra-
epithelial neoplasia. Infected males could only occupy
a single disease free state. For human papillomavirus
types 6 and 11 we used three type specific compart-
ments for both sexes, representing being susceptible to
infection, being infected, and being immune to human
papillomavirus infection.
People in infected states could regress to less severe
disease states or to the immune state as a result of
natural regression or cervical screening followed by
treatment. Natural immunity could wane, causing
people to again be susceptible to infection of the same
type. We used a range of possible values for the rate at
which infection was cleared and the rate at which
natural immunity was lost. Progression and regression
rates were determined by fitting models to data on
prevalence of human papillomavirus, results for
cervical screening, and diagnoses of cervical cancer.
Thevaccineshave shownclose to100%efficacyagainst
clinical end points in females naive to human
papillomavirus.11 The model simplifies these results
by assuming that vaccine protected people have 100%
protection against any vaccine type human papilloma-
virus infection.
We constructed a total of 2700 possible scenarios for
high risk papillomavirus types (or groups of types) and
900 scenarios for low risk types from combinations of
assumptions on the epidemiology of human papillo-
mavirus, clinical course of infection, accuracy of
cervical screening, and rates of sexual partnership. Of
these we chose outcomes from 72%of scenarios for the
economic analysis on thebasis of their goodnessof fit to
prevalence data on human papillomavirus.12 We then
generated parameter values for cost and utility weights
by Monte Carlo sampling (using the Latin hypercube
method) from the joint distribution of plausible ranges
of values for each parameter (see table 1). To estimate
the cost to the health service and benefits gained we
combined each set of economic parameters with one of
the transmission dynamic model scenarios. By sam-
pling from different combinations of epidemiological
and economic assumptions we constructed a total of
50 000 meta-scenarios.
We followed annual birth cohorts of 80 000 infants in
the transmission model for 100 years after the onset of
vaccination, with costs inflated to 2006-7 prices (in
sterling) according to the hospital and community
health services pay and price inflation index.13
Uninflated costs are presented in the text but are
inflated to 2006-7 prices in table 1. We measured
health utilities in quality adjusted life years (QALYs),
discounted costs and benefits at 3.5% per year in the
base case, and adopted a healthcare provider perspec-
tive on costs, as required by the National Institute for
Health and Clinical Excellence.14
Vaccination strategies
We analysed the cost effectiveness of a range of
vaccination strategies. The base case assumption was
vaccination of girls aged 12 years using a school based
programme, with 80% vaccine coverage (just under
400 000 girls) for the full three doses, on the basis of
reported coverage in a trial of a school based hepatitis B
vaccination programme.15 A pilot study in schools in
Manchester found the uptake of vaccine against human
papillomavirus to be as low as 70%,16 which we
considered in an alternative scenario. A proportion of
girls were assumed to receive only one or two doses, on
thebasis of reported figures from thehepatitisB study.15
Weassumed that those receiving fewer than threedoses
received no protection against human papillomavirus.
Alternative scenarios were vaccinating girls at ages 13
Threshold (£/QALY)
%
 o
f e
st
im
at
es
 t
ha
t a
re
 c
os
t e
ff
ec
ti
ve
0
20
40
60
80
100
10 0000 20 000 30 000 40 000 50 000 60 000
10 years
Base case
20 years
Base case + unscreened
Life long
Optimistic
Fig 1 | Cost effectiveness acceptability curves for base case
vaccination programme (girls aged 12 years only, quadrivalent
vaccine, 80% coverage) under different assumptions about
duration of protection from vaccine. Incremental cost
effectiveness of vaccination compared with no vaccination
option is shown.Regionof£20000-£30000perQALYgained is
shaded. Thick solid and dashed lines indicate cost
effectiveness acceptability curves when considering vaccine
type cervical cancers in a screened population, medium solid
and dashed lines indicate curves assuming 80% coverage in
screened and unscreened populations, and thin solid and
dashed lines indicate curves assuming 80% coverage in
screened and unscreened populations, protection against non-
cervical cancers, and some cross protection against non-
vaccine types
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or 14 instead, vaccinating boys and girls at age 12, a
catch-up campaign in the first year of vaccination to
vaccinate females from age 12 to ages 14, 16, 18, or 25,
and achieving a coverage of 70% or 90% for the full
three doses.
We analysed the cost effectiveness of two vaccines: a
vaccine that protects against human papillomavirus
types 6, 11, 16, and 18, and a vaccine that protects
against types 16 and18only (therefore does not protect
against anogenital warts). Analysis of each vaccination
strategy included the impact of vaccination on the
incidence of neoplasias, cervical cancer, and warts in
females and of warts in males. All base case analyses
used the quadrivalent vaccine. We assumed that
vaccinating people infected with human papilloma-
virus would have no effect on disease progression but
would protect them from subsequent infection, as
suggested by vaccine trials.6 Results from clinical trials
of the quadrivalent vaccine indicate that the vaccine
protects women for at least five years,17 but epidemio-
logical evidence beyond that time scale is lacking. We
therefore assumed the proportion of protected vacci-
nated women declined exponentially from the time of
vaccination, with the average duration of protection
varying between life long and 10 years.
To ensure reliable comparisons between strategies
weused the same set of 50 000meta-scenarios tomodel
each vaccination strategy.
Table 1 | Parameters used in economicmodel
Parameter Distribution Reference
Total cost (£):
Cervical screen Normal mean 55 (SD 4.4) 18; 13
Colposcopy Normal mean 216 (SD 81) 20
Treatment for precancerous lesions* Normal mean 332 (SD 27) 19; 20
Lifetime cost of cancer treatment
Stage I Lognormal based on normal mean 9.30 (SD 0.63) 28
Stage II Lognormal based on normal mean 9.68 (SD 0.82) 28
Stage III Lognormal based on normal mean 9.84 (SD 0.50) 28
Stage IV Lognormal based on normal mean 9.53 (SD 1.01) 28
Treatment for warts Normal 134 (SD 9.08) 34
Vaccine cost (per dose) Uniform 60.00, 80.50 Market price
Administration cost (per dose): school based Normal mean 4.37 (SD 1.09) 15
Administration cost (per dose): general practitioner based Normal mean 10 (SD 2.5) 13
Total QALY detriment:
Positive Pap smear result received Normal mean 0.03 (SD 0.015) 24; 26; 27
Colposcopy result received
Cervical intraepithelial neoplasia grade 1 Normal mean 0.012 (SD 0.031) 24; 26; 27
Cervical intraepithelial neoplasia grade 2 Normal mean 0.065 (SD 0.0051) 24; 26; 27
Cervical intraepithelial neoplasia grade 3 Normal mean 0.054 (SD 0.051) 24; 26; 27
Year of treatment
Cancer stage I Normal mean 0.35 (SD 0.082) 29
Cancer stage II Normal mean 0.44 (SD 00.71) 29
Cancer stage III Normal mean 0.44 (SD 0.071) 29
Cancer stage IV Normal mean 0.52 (SD 0.061) 29
Year of post-treatment
Cancer stage I Normal mean 0.10 (SD 0.066) 29
Cancer stage II Normal mean 0.15 (SD 0.077) 29
Cancer stage III Normal mean 0.15 (SD 0.077) 29
Cancer stage IV Normal mean 0.38 (SD 0.061) 29
Warts diagnosed Normal mean 0.039 (SD 0.017) 32
Sensitivity for cervical intraepithelial neoplasia grade 1 Triangular 0.17, 0.69, 0.99 23
Specificity for cervical intraepithelial neoplasia grade 1 Triangular 0.09, 0.81, 1.00 23
Sensitivity for cervical intraepithelial neoplasia grades 2 or 3 Triangular 0.23, 0.83, 1.00 23
Specificity for cervical intraepithelial neoplasia grades 2 or 3 Triangular 0.21, 0.92, 1.00 23
Years after treatment with reduced life quality Triangular 0, 5, 100 Assumed
Multiplier for cancer survival rates Normal mean 1.00 (SD 0.022) 29
Duration (days) of anogenital warts episode Normal mean 52.6 (SD 5.08) 31
Proportion of girls receiving only 1 dose Normal mean 2 (SD 0.5) 14
Proportion of girls receiving only 2 doses Normal mean 9 (SD 2.25) 14
QALY=quality adjusted life years. £1.00 (€1.26; $1.98).
*Cervical intraepithelial neoplasia grades 1, 2, or 3.
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Economic parameters
Screening
Cervical screening in the UK is currently carried out
using the Pap smear, although this is being replaced by
liquid based cytology.We therefore estimated the cost
of a screen as the midpoint between the costs of a
conventional Pap smear (£21.70,18 2002 prices) and
liquid based cytology (£25.40,19 2003 prices). We
added the costs of consultations with a general
practitioner (£2.50 per minute,13 2006 prices) on the
basis of average consultation timesof 13.3minutes for a
Pap smear and 8.6 minutes for liquid based cytology.18
Costs for screening at sexual health clinics and
outpatient clinics are higher (£37 20 and £6819
respectively, 2003 prices), but we did not use them as
they account for under 10% of screens.21 We assumed
the cost of a colposcopy to be normally distributed,
with distribution parameters following standard NHS
reference costs.22
We estimated the number of screens and colposco-
pies per woman on the basis of the UK screening
protocol, and estimates of sensitivity and specificity of
the Pap smear.23 The sensitivity and specificity of the
Pap smear were varied over the range suggested by
Nanda et al.23 The range is wide enough to encompass
possible improvements resulting from the introduction
of liquid based cytology. Estimates of the quality of life
detriment while waiting for follow-up after a positive
Pap smear result or a positive colposcopy result were
based on questionnaires given to healthy volunteers.24
We assumed the waiting period for a follow-up Pap
smear to be six months and for a colposcopy one
month, as recommended by guidelines from the NHS
cervical screeningprogramme.25 If awoman received a
positive colposcopy result we assumed that she would
wait 1.6 months for follow-up after a cervical intra-
epithelial grade 1 result, 0.6 months after a grade 2
result, and 5.0 months after a grade 3 result.26 We
sampled quality of life detriment during this time from
a normal distribution centred around time trade-off
estimates from a survey of university students.24 We
fixed the variance to ensure that much lower estimates
of quality of life detriment using committee consensus
health utility index estimates from an Institute of
Medicine report27 would be the lower 95% centile of
the distribution. Treatment costs after a positive
colposcopy result ranged from £280 (2004 prices) per
treatment for large loop excision of the transformation
zoneusingdata fromprivate insurers’ fee schedules20 to
£329 (2004 prices) per treatment for cone biopsy or
large loop excision of the transformation zone using
NHS reference costs.19 We used these two results to
estimate the mean and variance of a normally
distributed parameter for the relevant treatment cost.
Cancer
We stratified the average treatment costs28 and quality
of lifeweights29 associatedwith treatment for each stage
Table 2 | Discounted costs and quality adjusted life years (QALYs) gained byhuman papillomavirus vaccination in base case
programme(vaccinationofgirlsaged12yearswithnocatch-upprogramme,80%effectivevaccinecoverage,quadrivalentvaccine,
100 year timehorizon, and 3.5%discount rate for costs and benefits) assuming vaccine protection lasts an average of 20 years
Parameter Mean Median 5% centile 95% centile
Cost of vaccine (£m) 2225 2225 1937 2513
Cost saved (£m):
Reduced lesion screening and treatment −48 −47 −176 61
Cancers prevented −135 −118 −274 −55
Warts prevented −229 −232 −300 −151
Net cost (£m) 1813 1816 1455 2169
Cost saved (£m):
Unscreened vaccinees −16 −14 −34 −7
Non-cervical cancers prevented −42 −34 −96 −16
Non-vaccine type infections prevented −61 −55 −110 −34
Net cost with unscreened, non-cervical cancers, and non-
vaccine type infections (£m)
1694 1701 1288 2074
QALYs gained:
Reduced lesion screening and treatment 10 987 9 617 −783 27 607
Cancers prevented 63 353 60 976 44 326 90 051
Warts prevented 9530 9233 4434 15 711
Total QALYs gained 83 871 80 690 58 856 119 167
QALYS gained:
Unscreened cohort 7444 6778 5048 12 137
Non-cervical cancers prevented 18 033 15 171 11 085 34 924
Non-vaccine type infections prevented (£m) 8799 7989 5378 15 531
Total QALYs gained with unscreened, non-cervical cancers,
and non-vaccine type infections
118 146 111 304 82 874 177 199
£1.00 (€1.26; $1.98). Mean, median, 5% and 95% centiles of 50 000 meta-scenarios representing uncertainty in epidemiological and economic
parameters are reported.
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of cervical cancer by age at time of detection according
to the classification given by the International Federa-
tion of Gynecology and Obstetrics. We used age
groups of 10-49, 50-69, and 70 or more; these
correspond to those used in a Dutch study of survival
rates in patients with cervical cancer.30 Mortality rates
for patients aged 50 or more were increased by 12.5%
to account for reported differences in survival from
cervical cancer in older patients between the Nether-
lands and England.31 We assumed treatment for
cervical cancer to last five years unless the patient
died before that time. To determine the number of
years between a diagnosis of cancer and death in non-
survivors we used five year survival curves.30 Rates
were varied in the sensitivity analysis within their
reported 95% confidence intervals. We assumed that
patients who survived beyond five years had a normal
life expectancy but reduced quality of life.29 The length
of time spent in this state of reduced quality of life was
assumed to vary between no years to the remaining
lifetime of the recovered patient. We sampled quality
of life detriments associatedwithpatients and survivors
of cancer from normal distributions fitted to the base
case and range used in a previously publishedmodel.29
Healthcare costs of treating patients with cancer are
available from an audit of the Trent Cancer Registry28;
we fitted the reportedmeans and standarddeviations to
a lognormal distribution. We assumed that costs and
quality of life detriments for non-cervical cancers were
the same as for cervical cancers.
Warts
Quality of life of patients with anogenital warts was
estimated on the basis of data from a cross sectional
survey of 81 attendees to a sexual health clinic in York
using the EQ-5Dquestionnaire.32We did not use other
published data as they were based on interviews with
healthy volunteers or doctors24 27 or on studies with
small sample sizes.33 The cost of treating an episode of
anogenital warts was £134 (2006 prices), estimated
from an audit of 189 case notes in the same clinic.34We
includednewand recurrent cases in the analysis.This is
slightly lower than previous estimates in the literature,
which range between £18035 and £19120 when adjusted
to 2007 prices. We used the same notes to estimate the
length of an episode of warts, defined as the time from
first attendance forwarts andendingwhenapatientwas
either declared free of warts, did not subsequently
return after being instructed to return only if warts
recurred, or was lost to follow-up. We assumed that
patients lost to follow-up after only a single visit had an
episode length of 28 days (the average length of a
prescription for home treatment for warts given by the
clinic). Patients who still had warts at the end of the
study period were censored. We added an additional
seven days to the length of each episode of warts to
represent the time between the appearance of symp-
toms and attendance at the clinic.
Vaccination costs
We varied the cost for a dose of the quadrivalent
vaccine between £60 (catalogue price ofGardasil in the
United States; Merck, NJ) and £80.50 (price at which
Gardasil is currently available privately in the UK36;
Sanofi PasteurMSD,Berks).Thecost of administration
was estimated at £3.56 per dose (2001 prices), based on
the estimated administration cost of hepatitis B
vaccination by a school based programme.15 For
catch-up campaigns, females aged over 16 years were
assumed to receive their vaccination through general
practice clinics and hence instead incur a cost of £10
(2006 prices) for a nurse consultation.13
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Fig 2 | Cost effectiveness acceptability curves for vaccination of
girlsaged12,13,or14yearswithaquadrivalentvaccineat80%
coverage, under different assumptions about vaccine duration
of protection, based on results of 50000 meta-scenarios
combining epidemiological and economic assumptions.
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Fig 3 | Cost effectiveness acceptability curves for vaccination of
girls aged 12 years with a quadrivalent vaccine at different
levels of three dose coverage, for different assumptions about
duration of protection from vaccine. Incremental cost
effectiveness of vaccination compared with no vaccination
option is shown. Region of £20000-£30000 perQALY gained is
shaded
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Alternative scenarios
Vaccinating unscreened women
The transmission model considers the effect of human
papillomavirus vaccination in a screened population.
We considered in a separate scenario estimates of
vaccine impact on cancers in unscreened women by
setting screening rates to zero. The size of the
unscreened population was assumed to be 3.8% of
the entire cohort of females eligible for screening,
based on the proportion of women aged 45-49 years
estimated to have never attended screening.21 To
estimate the maximum possible benefit from vaccina-
tion, we assumed that a human papillomavirus vaccine
reduces the incidence of cancer in unscreened women
in a particular age group by the median proportion it
reduces the incidence of cancer in screened women in
the same age group. This is an overestimate as it
assumes that the maximum reduction occurs immedi-
atelyafter vaccinationand that cervical cancersoccurat
the same age in screened and unscreened women.
Vaccine impact on non-cervical cancers
Worldwide, oncogenic human papillomavirus types
may be linked to 90% of anal cancers, 40% of vulval,
vaginal, and penile cancers, and 12% of oropharyngeal
cancers.5 The quadrivalent vaccine has shown good
efficacy against vulval andvaginal neoplasias in clinical
trials,37 and it is possible that the vaccines would be
effective against non-cervical cancers caused by
vaccine type human papillomavirus. We therefore
estimated the additional benefit of assuming that both
vaccines are fully effective against vaccine type
infections leading to non-cervical cancers. The annual
incidence of such cancerswas obtained from theOffice
forNational Statistics,1 whereas the proportion of these
cancers attributable to human papillomavirus types 16
and 18 was obtained from a seroprevalence study
among patients with anogenital cancer.38 We did not
include estimates in the base case because of the
uncertainty about whether vaccination fully protects
against all these cancers and the lack of reliable
information about the fraction attributable to each
human papillomavirus type and the progression to
disease.
Vaccine impact on non-vaccine types
In the base case we assumed that vaccination afforded
no protection against non-vaccine type human papil-
lomavirus infection. Some protection against non-
vaccine types has been suggested in clinical trials of
both vaccines, however.7 8 We considered the addi-
tional reduction in cervical cancer incidence of cross
protection with an efficacy of 27% against oncogenic
non-vaccine types as suggested in the literature.
Analysis of individual parameter contribution
We analysed the relative contribution of each epide-
miological and economic parameter on the
Table 3 | Cost effectiveness of alternative human papillomavirus vaccination options of catch-up campaigns and vaccinating girls
and boys, comparedwith base case vaccination option of vaccinating girls aged12 years only
Programme
Average cost effectiveness ratio* (£) Incremental cost effectiveness ratio† (£)
Median 5% centile 95% centile Median 5% centile 95% centile
10 years’ vaccine protection:
Girls aged 12 33 868 18 632 49 828 33 868 18 632 49 828
Catch-up aged 12-14 33 296 18 464 48 987 26 448 16 389 39 176
Catch-up aged 12-16 32 244 17 978 47 535 20 808 12 179 31 807
Catch-up aged 12-18 31 132 17 447 45 657 16 989 503 54 405
Catch-up aged 12-25 39 096 21 785 57 883 136 329 61 405 702 610
Girls+boys aged 12 53 099 31 696 77 780 113 846 71 099 176 749
20 years’ vaccine protection:
Girls aged 12 22 474 13 722 32 920 22 474 13 722 32 920
Catch-up aged 12-14 22 210 13 636 32 553 18 856 12 296 27 992
Catch-up aged 12-16 21 789 13 420 31 996 16 417 10 238 25 117
Catch-up aged 12-18 21 126 13 061 30 898 11 856 Cost saving 31 107
Catch-up aged 12-25 27 432 17 069 40 327 128 302 64 003 557 772
Girls+boys aged 12 42 211 28 011 60 581 172 892 112 230 289 698
Lifetime vaccine protection:
Girls aged 12 15 094 10 093 22 032 15 094 10 093 22 032
Catch-up aged 12-14 14 992 10 058 21 899 13 637 9297 20 493
Catch-up aged 12-16 14 877 10 004 21 760 13 204 8797 20 259
Catch-up aged 12-18 14 687 9912 21 453 11 509 2478 23 568
Catch-up aged 12-25 19 476 13 443 28 366 105 839 62 493 337 016
Girls+boys aged 12 33 281 23 814 46 994 520 255 304 798 986 917
£1.00 (€1.26; $1.98).
*Cost effectiveness of particular option compared with no vaccination option.
†Ratio of additional costs and benefits of particular vaccination programme compared with previous option. Options being compared with is no
vaccination when considering routine vaccination of girls aged 12, routine vaccination of girls aged 12 when considering routine vaccination of both
sexes aged 12, and programme listed immediately before for each of catch-up campaign options.
RESEARCH
page 6 of 12 BMJ | ONLINE FIRST | bmj.com
incremental cost effectiveness of vaccination. Epide-
miological scenarios were converted into integer
codes. For example, the duration of natural immunity
was codedas 0 fornone, 1 for threeyears, 2 for 10years,
3 for 20 years, and 4 for life long. We used each
epidemiological scenario and each economic para-
meter in table 1 as a predictor variable in a linear
regression model, with the cost per QALY gained as
the outcomevariable. To correct for heteroskedasticity
we used robust standard errors. We chose parameters
in the model by using backward stepwise regression
with a significance cut-off of 0.05. Each coefficient was
thenmultiplied by the end points of the corresponding
95% confidence interval for the parameter (based on
the distributions shown in table 1) to obtain a predicted
range for the cost effectiveness ratio as each parameter
was varied.
Price differential for quadrivalent and bivalent vaccines
For thebase case scenariowedetermined the estimated
price differential between equally cost effective biva-
lent and quadrivalent vaccines. The price differential
was calculated by dividing the net present value of the
additional benefits of a quadrivalent vaccination
programme for preventing anogenital warts (cost
savings to the health service and quality of life gains)
by the number of doses of vaccine required to achieve
the benefits. The net present value was calculated on
thebasisof awillingness topay thresholdof£30 000per
QALY gained, based on the perception that this is
approximately the cost effectiveness threshold used for
evaluating health technologies in the UK.39
RESULTS
The median cost per QALY gained of the base case
scenario (vaccinating girls aged 12 at 80% coverage
with a quadrivalent vaccine) with vaccine protection
for an average of 20 years is £22 500 (95% range
£13 800-£32 900). The median net discounted cost of
the programme over 100 years (cost of vaccination
minus cost to the health service saved due to reduction
in human papillomavirus related outcomes) is £1.8bn
(95% range £1.5bn-£2.2bn, table 2).
Epidemiological impact of vaccination
Model results10 predict that vaccinating 12 year old
girls in a screened population at 80% coverage with a
quadrivalent human papillomavirus vaccine that
protects for an average of 20 years reduces the
incidence of cervical cancer by 24-93% and anogenital
warts by 22-100% after 100 years of an ongoing
vaccination programme. Catch-up campaigns reduce
incidence in the first 30 years of vaccination but have
little effect beyond that. Extending vaccination to boys
provides only a small additional reduction in incidence
of cervical cancer and anogenital warts, with the
greatest benefit when the duration of vaccine protec-
tion is short.
Cost effectiveness
Table 2 shows the cost and QALYs gained by the
introductionof vaccination, over the 100years after the
introduction of the vaccine, assuming base case
assumptions (vaccination of girls at age 12, 80%
coverage, quadrivalent vaccine, and no catch-up
programme) and vaccine protection lasting on average
20 years. The vaccination programme is expected to
generate cost savings to the health service from
reduced treatment. These are, however, outweighed
by the cost of the vaccination programme itself,
estimated to be £77m (95% range £68m-£88m) a
year. Hence vaccination is unlikely to be cost saving.
QALYsare gained througha reduction in thedetection
and treatment of cervical dysplasia (or presumed
cervical dysplasia), anogenital warts, and cervical
cancer. Roughly three quarters of the discounted
QALYs gained result froma reduction in the incidence
of cancer. A reduction in the incidence of warts
contributes to about a 10th of discounted QALYs
gained but to about half of the discounted cost savings
to the health service.
Table 2 also shows the additional cost savings and
QALY gains from protecting the unscreened popula-
tion, protecting against non-cervical cancers linked to
humanpapillomavirus, andpartiallyprotecting against
infection by non-vaccine human papillomavirus types.
Of the three categories, the QALY benefit from
preventing non-cervical cancers is greatest. However,
the figures assume these cancers follow a similar
progression to cervical cancers. Partial protection
against infection by non-vaccine human papilloma-
virus types has the greatest potential for cost savings, as
these types account for a large portion of positive
cervical smear results that then require expensive
follow-up procedures. TheQALY gains from prevent-
ing these infections are smaller because these human
papillomavirus types account for a minority (about
30%) of cervical cancers in the UK.
Figure 1 shows cost effectiveness acceptability curves
for thisvaccinationprogramme,givendifferent assump-
tions about the duration of protection from the vaccine.
The results suggest that if vaccine induced immunity is
short lived (10 years on average) then it is unlikely that
vaccination of 12 year old girls would be acceptable on
Table 4 | Estimated price differential between equally cost effective bivalent and quadrivalent
human papillomavirus vaccines (vaccination of girls aged12 years, 80%effective vaccine
coverage, 100 year timehorizon, and 3.5%discount rate for costs and benefits)
Age at vaccination and catch-up
Duration of vaccine protection
10 years 20 years Life long
Girls aged 12 only:
Median (£) 12.96 17.27 20.94
95% centile (£) 22.06 26.59 30.30
5% centile (£) 6.26 9.37 12.95
Girls aged 12 with catch-up to age 18:
Median (£) 15.54 20.28 23.21
95% centile (£) 25.26 29.91 32.79
5% centile (£) 8.58 12.28 14.98
£1.00 (€1.26; $1.98).
Results are based on 50 000 meta-scenarios representing uncertainty in epidemiological and economic
parameters.
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the grounds of cost effectiveness (a small proportion of
the simulations result in a cost per discounted QALY
gained of less than £20000-£30000). If the vaccine
induces lifelong protection, however, then more than
80% of scenarios suggest that vaccination would be
regarded as cost effective (below £20000-£30000 per
QALY gained). If vaccine induced immunity lasts on
average around20years thenabout 25-85%of scenarios
suggest that the vaccination programme is cost effective
(fig 1). Figure 1 also shows cost effectiveness accept-
ability curves resulting from the use of more optimistic
assumptions. Assuming that vaccine uptake is 80% in
girls who do not subsequently attend cervical screening
is not sufficient to make a vaccine with 10 years’
protection cost effective. If this assumption is used and
thevaccine is also assumed tobeefficacious against non-
cervical cancers and partially efficacious against infec-
tion by non-vaccine human papillomavirus types, then
vaccination may be cost effective even if vaccine
induced immunity lasts only 10 years on average.
Age at vaccination
Figure 2 shows that offeringvaccination to girls aged13
or 14 instead of 12 (as in the base case) increases the
likely cost effectiveness of the programme, particularly
if vaccine induced immunity is not life long. This is for
two reasons: firstly, vaccinating at a slightly older age
means that thedelay tobenefits beingaccrued is shorter
and as health benefits are discounted this more rapid
accrual of benefits is preferred. Secondly, if vaccine
induced immunity is relatively short lived (10-20 years
on average), and declines exponentially (as assumed)
then delaying vaccination for a few years results in
greater protection for women during the highest risk
period for acquisition of human papillomavirus (late
teens and 20s). It has not, however, been assumed that
there are increased costs or a drop-off in coverage
associated with vaccinating at a later age. Also, these
findings depend on the low prevalence of human
papillomavirus infection before age 14 in theUK40 and
are not generalisable to countries in which sexual
activity starts at an earlier age. The additional benefit of
delaying vaccination by one or two years of life is most
clearly seen for reduction in the incidence of warts,
because this peaks in the early 20s and because the best
fitting scenarios for warts related human papilloma-
virus types (6 and 11) are associated with a short
duration of natural immunity. Extending vaccine
protection by just a few years can therefore have a
large effect on the acquisition of wart related human
papillomavirus types.
Vaccine coverage
The cost perQALYgainedof vaccination is insensitive
to vaccine coverage in girls over the range explored
(70-90%). This is because there is an approximately
linear relation between coverage and the reduction in
disease as well as a linear relation between coverage
and the costs of the programme. Although greater
coverage increases the costs and benefits of the
programme it does not significantly alter the cost per
QALYgained (fig 3).Theeffect of reducingcoverage to
below 70% was not explored. Models of vaccination
against human papillomavirus in developing
countries41 42 suggest that levels of coverage around
50% may be more cost effective than higher levels of
coverage, perhaps because of the increased benefit
from herd immunity.
Vaccination of boys
Vaccinationofboys at age12years in addition togirls is
unlikely to be cost effective, even if vaccination results
in lifelong protection (table 3). This is because at 80%
coverage it is likely that most cervical cancers due to
human papillomavirus types 16 and 18 will be
prevented along with many cases of anogenital warts
(in both sexes). Therefore the additional benefits from
vaccination of boys are few. This is particularly true if
the duration of vaccine protection is long, as there is
little additional burden to avoid.
Catch-up campaigns
Table 3 shows that a catch-up campaign in girls up to
age 18 may be cost effective, but extending the
campaign to age 25 is highly unlikely to be cost
effective. Campaigns up to age 18 aremore likely to be
cost effective than the base case programme, because
vaccinating at a slightly older age is more cost effective
than vaccinating at age 12. This implies that if the base
case programme is viewed favourably, then vaccinat-
ing girls up to age 18 in an initial catch-up campaign
should also be adopted. Above this age an increasing
proportion of females have previous evidence of
human papillomavirus infection, and the delivery
costs increase because it is assumed that vaccination
in females older than 16would be offered through their
general practitioners rather than in a school based
programme. A campaign up to age 18 actually weakly
dominates shorter catch-up campaigns; however,
Duration of vaccine protection Life long
None
£60.00
0.23
100.00
0.11
0.15
1.00
121
10 years
Long
£80.50
0.00
0.00
0.00
0.00
0.09
68
Duration of natural immunity
Cost: dose of quadrivalent vaccine
QALY loss: post-treatment cancer stage 1
(per year)
Pap smear test: sensitivity to cervical
intraepithelial neoplasia grades 2 or 3
QALY loss: receive cervical intraepithelial
neoplasia grade 2 biopsy result
QALY loss: receive cervical intraepithelial
neoplasia grade 3 biopsy result
Pap smear test: specificity to cervical
intraepithelial neoplasia grade 1
Duration (days) of warts episode
£15 000£10 000 £20 000 £25 000 £30 000 £35 000 £40 000
Fig 4 | Results of sensitivity analysis. Effect of changing each parameter over its range on
estimated cost effectiveness of base case programme (estimates derived from regressionmodel).
95% end points of range of each parameter are also shown
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shorter campaigns have been included in the analysis
because it would be politically and operationally
difficult to apply a combination of two strategies to
the same population. 43
Price differential for quadrivalent and bivalent vaccines
Table 4 shows the estimated price differential between
equally cost effective bivalent and quadrivalent vac-
cines for different assumptions about the vaccines’
average duration of protection. A bivalent vaccine
would have to be around £13-£21 less expensive per
dose for it to be as cost effective as an equivalent
quadrivalent vaccine in a vaccination programme
directed at 12 year old girls. The price differential is
greatest if the vaccines both give lifelong protection. If
the programme was extended with a catch-up pro-
gramme for girls up to age 18, then the bivalent vaccine
would have to be around £15-£23 less expensive per
dose. Catch-up campaigns make the quadrivalent
vaccine slightly more cost effective than the bivalent
vaccine if the duration of vaccine protection is not life
long,because theyenablea largerportionof theburden
of anogenital warts (which peaks in the early 20s) to be
prevented.
Sensitivity analysis
Figure 4 shows the parameters in the linear regression
model that produce the largest variation in the cost
effectiveness ratio. The most important determinants
of the cost effectiveness of the programme are the
average duration of vaccine protection and of natural
immunity. Vaccination has the greatest impact (and
therefore is most likely to be cost effective) if the
duration of protection is long and the duration of
natural immunity is short. Table 5 shows the effect of
altering the discount rate. The cost effectiveness ratio is
highly sensitive to thediscount rate forbenefits because
most of the QALY gains from preventing cervical
cancers occur decades after the vaccination pro-
gramme begins.
DISCUSSION
Our economic analysis indicates that vaccinating
12 year old girls through a school based programme
with a quadrivalent human papillomavirus vaccine
priced at around £60-£80 per dose is likely to be cost
effective at a threshold of £20 000-£30 000 per QALY
gained as long as vaccine inducedprotection lastsmore
than 10 years. If the duration of protection is only
10 years then the programmemay still be cost effective
if highvaccineuptake canbe achievedamonggirlswho
do not subsequently attend screening, if the vaccine is
highly efficacious against non-cervical cancers caused
by human papillomavirus types 16 and 18, and if it is
partially efficacious against cervical cancers not caused
by human papillomavirus types 16 and 18. Several
parameters and model assumptions had a strong
influence on the costs and health gains from human
papillomavirus vaccination, in particular the duration
of vaccine induced protection and the duration of
natural immunity after infection with human papillo-
mavirus. Results from the models also suggest that an
initial catch-up campaign covering girls up to age 18 is
likely to be cost effective, but vaccination of boys is
unlikely to be cost effective.
Strengths and weaknesses
A large number of possible model structures can be
parameterised to match epidemiological data. Our
approach involvedanexhaustive searchof this spaceof
possible structures, fitting themodels to available data,
followed by sampling from the distribution of eco-
nomic parameters. The range of models we have
presented represent uncertainty in natural immunity to
human papillomavirus infection; the sensitivity of the
screening test; progression and regression between
precancerous states; the prevalence of human papillo-
mavirus types by age; the range of sexual partnerships
in theUKpopulation; and the impact of vaccination on
other high risk types, the unscreened population, and
non-cervical cancers.
Many other features of the biology of human
papillomavirus are uncertain but were not varied as
part of our uncertainty analysis. These include time
dependent rates of loss of vaccine induced immunity
and replacement of virus type by other human
papillomavirus types after vaccination, as well as
natural and vaccine induced cross immunity, synergy,
or antagonism in progression rates for women infected
with several types of human papillomavirus.
Only the 72% of model structures that best fit
prevalence data for human papillomavirus were used
Table 5 | Effect of altering discount rate on incremental cost effectiveness ratio of base case
programme (vaccination of girls aged12 years, 80%effective vaccine coverage, 100 year time
horizon, and 3.5%discount rate for costs and benefits)
Discount rate
Incremental cost effectiveness ratio (£)
Median 5% centile 95% centile
10 years’ vaccine protection:
3.5% costs and benefits 33 868 18 632 49 828
5.0% costs and benefits 48 911 27 369 70 907
0% costs and benefits 11 273 5389 17 005
3.5% costs, 0% benefits 3446 1799 5084
6.0% costs, 1.5% benefits 5225 2887 7592
20 years’ vaccine protection:
3.5% costs and benefits 22 474 13 722 32 920
5.0% costs and benefits 33 115 20 690 47 626
0% costs and benefits 7017 3692 10 762
3.5% costs, 0% benefits 2238 1339 3290
6.0% costs, 1.5% benefits 3495 2201 5032
Lifetime vaccine protection:
3.5% costs and benefits 15 094 10 093 22 032
5.0% costs and benefits 22 785 15 617 32 470
0% costs and benefits 4320 2395 6794
3.5% costs, 0% benefits 1470 993 2132
6.0% costs, 1.5% benefits 2385 1685 3348
£1.00 (€1.26; $1.98).
Results are based on 50 000 meta-scenarios representing uncertainty in epidemiological and economic
parameters.
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in the analysis, but care should be taken when
interpreting model results not to assume that each of
the remaining model structures is equally plausible.
Because of this the mean or median cost effectiveness
ratio of the range of scenarios considered is not
necessarily a reliable predictor of the most likely
value for an actual vaccination programme. Instead,
the entire range of results should be considered. In
many cases most of the scenarios lie on one side of the
£20 000-£30 000 per QALY gained threshold, indicat-
ing that reliable conclusions can be drawn about the
cost effectiveness of a programme even if the more
likely scenarios may be unequally distributed within
the range of outputs.
Comparison to other studies
Todateonly threepublishedmodels have lookedat the
impact of vaccination in the UK.44-46 Two4446 are static
models that do not consider the benefits of herd
immunity. Thus they underestimate the cost effective-
ness of human papillomavirus vaccination and cannot
meaningfully estimate the cost effectiveness of vacci-
nating boys, as this is influenced by the impact that
vaccinating girls alonewould have on boys. One of the
models44 does not present cost or utility implications of
epidemiological outcomes. Also, existing models of
humanpapillomavirus vaccinationhaveeither ignored
adenocarcinomas46 or assumed that they behave in
exactly the sameway as squamous cell carcinomas.44 45
We estimated the impact of vaccination on non-
vaccine human papillomavirus types and considered
the impact of vaccination on non-cervical cancers,
whichonly a fewrecentmodels47 48 have included.Both
these benefits are important to consider as they have
been claimed by the vaccine manufacturers.
Model predictions about the cost effectiveness ratio
assuming lifelong vaccine induced protection are
broadly in line with base case results from other
published models of human papillomavirus vaccina-
tion in developed countries.44-47 49 50 Our findings are
likely tobemore robust thanmost of theseowing to our
more exhaustive treatment of epidemiological uncer-
tainty. Existing UK models44-46 are limited in terms of
sensitivity analysis as they do not take full account of
the many biological, epidemiological, and economic
uncertainties surrounding human papillomavirus vac-
cination. Such models have assumed a base case
structure and performed sensitivity analysis around
the parameter values one or two at a time. For the case
of humanpapillomavirus it is difficult to justify a choice
of base case because of the uncertainty around many
key parameters, and indeed the structure of the model
itself. Only two published cost effectiveness models on
human papillomavirus (from Canada50 and Brazil41 42)
have performed multivariate sensitivity analyses on
model structure. Neither of these are transmission
dynamicmodels, although theBrazilianmodel41 42 uses
post-vaccination incidences from a separate transmis-
sion model.
Implications and future research
Cervical screening has significantly reduced the
incidence of cervical cancer.51 Although we have
included the estimated impact of screening in the
model and tried to account for the accuracy of
screening in our results, some of the details of the
programme (such as rescreening women more often
after a suspect result) are difficult to properly imple-
ment in the current model structure. In addition,
although we attempted to estimate the impact vaccina-
tion may have on the unscreened population, accurate
predictions of this depend on knowledge of who the
unscreenedpopulationare (some are likely tobe recent
immigrants and therefore not reachable by a school
based vaccination programme) as well as the possible
rates of vaccine uptake in these groups. We found that
the benefits of reaching unscreened groups can be
significant. Since vaccination could act to either
increase or decrease health inequalities depending on
the uptake rates for screening and vaccination by
socioeconomic groups and the level of herd protection
generated, future modelling and surveillance work
should deal with these aspects. Furthermore, our
model assumes that the screening programme will
continue unchanged, which is likely in the short term,
particularly as current vaccines against human papillo-
mavirus cannot provide full protection against all
oncogenic human papillomavirus types. If the pre-
valence of human papillomavirus infection is, how-
ever, significantly reduced as a result of universal
vaccination, as our model predicts, then it may be
possible to extend the interval between routine screens
or to increase the age at which screening is first offered,
as suggested inother cost effectiveness studies.29 52 Such
analyses would also need to take account of possible
changes to the cervical screening programme, such as
the introduction of DNA testing for human papilloma-
virus, as changes in the prevalence of infection after
vaccination would be expected to alter the attractive-
ness of screening testswith improved sensitivity (which
is provided by testing for human papillomavirus). It is
clear that significant further work on the design of
optimal screening and vaccination programmes is
required, particularly if the introduction of vaccination
WHAT IS ALREADY KNOWN ON THIS TOPIC
Human papillomavirus (HPV) vaccination could decrease the incidence of cervical and other
cancers and anogenital warts
ExistingeconomicanalysesofHPVvaccinationdonotconsidermanyof thepossiblesourcesof
epidemiological and economic uncertainty or end points that vaccination may prevent
WHAT THIS STUDY ADDS
Routinevaccinationofgirlsaged12combinedwithan initial catch-upcampaignuptoage18is
likely to be cost effective in the UK
Vaccination of boys is unlikely to be cost effective
A vaccine against HPV types 16 and 18 costing £13-£21 less per dose (depending on duration
of vaccineprotection)would beas cost effective asa vaccineagainst virus types6, 11, 16, and
18
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accelerates the recent trend for the declining uptake of
screening.21
Models are simplifications of reality and the
strengths of the conclusions drawn from modelling
studies depend on the reasonableness of the assump-
tions and parameters that make up the model. By
adopting a range of assumptions and parameter
estimates the approach taken here should generate
more robust conclusions than can be derived from
studies in which a single model structure is chosen and
sensitivity analysis done on the parameter values one
or two at a time. Although considerable uncertainty
remains, the study also highlights the areas of research
that could be taken to reduce this uncertainty.With the
adoption of human papillomavirus vaccination in the
UK and other countries, some of the other aspects of
the clinical course of human papillomavirus should
become apparent. High quality surveillance combined
withmathematical models will, however, be needed to
help disentangle the complex epidemiological patterns
that are likely to emerge after immunisation. Refine-
ment of these mathematical and economic models will
be necessary to help optimise screening and vaccina-
tion programmes in the future.
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